WORK Medical Technology Group LTD (WOK) AI Stock Analysis

• Market Cap: $1.63M
• Dividend Yield: N/A
• Average Volume (3M): 33.96M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.90
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 216
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): N/A
• Shares Outstanding: 1,219,255
• 10 Day Avg. Volume: 36,631,792
• 30 Day Avg. Volume: 33,957,643
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.12
• Price to Sales (P/S): 0.22
• P/FCF Ratio: 0.44
• Enterprise Value/Market Cap: 1.45
• Enterprise Value/Revenue: 0.24
• Enterprise Value/Gross Profit: 1.01
• Enterprise Value/Ebitda: -1.70
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: $1.50 ▼(-28.57% Downside)
• Action: Reiterated Date: 02/07/26
• Date: Action: Reiterated 02/07/26

The score is held back primarily by deteriorated profitability and contracting revenue, alongside bearish technical momentum. Offsetting this, leverage improved and cash flow rebounded in the latest year, but the lack of meaningful valuation support (negative earnings and no dividend data) keeps the overall profile below average.

Positive Factors

Improved leverage / balance sheet health

Lower debt-to-equity materially reduces balance-sheet risk and interest burden, giving the company more financial flexibility. Over the next 2–6 months this supports capacity to fund operations, invest selectively or withstand revenue headwinds without immediate refinancing pressure.

Rebounded operating and free cash flow

A return to positive operating and free cash flow signals improved cash generation and liquidity convertibility. This strengthens the company's ability to fund working capital, non-dilutive investment, or de-risk near-term funding needs, although consistency remains a monitoring point.

Established capacity to raise significant capital

Access to a $200M equity sales agreement provides a durable financing option to support growth, R&D, or balance-sheet repair. Over months this enhances strategic optionality and liquidity buffers, enabling management to execute plans without immediate cash constraints.

Negative Factors

Contracting revenue and persistent losses

Declining top line and negative margins indicate structural demand or competitive challenges that limit profitable scale. Persisting revenue contraction reduces ability to leverage fixed costs, undermines long-term return on capital, and constrains reinvestment without clear demand recovery.

Insider consolidation of voting control

A single insider controlling majority voting power can entrench leadership and prioritize insider objectives. Over the medium term this raises governance risk for minority holders, may enable related-party decisions or limit oversight, and can affect strategic alignment with outside investors.

Broad capital-restructuring powers and dilution risk

Proposed sweeping capital changes give the board broad discretion to reshape the capital base, lowering par value and enabling substantial issuance. Structurally this increases dilution risk, can weaken shareholder economic rights, and may be used to raise capital on terms unfavorable to existing holders.

WORK Medical Technology Group LTD Business Overview & Revenue Model

Company Description

WORK Medical Technology Group LTD, together with its subsidiaries, manufactures and sells medical consumables in the People's Republic of China and internationally. The company offers disposable medical devices, such as medical face masks, artery compression tourniquets, endotracheal tube holders, intubating stylets, and guedel airways, etc.; disposable breathing circuits, laryngeal mask airways, endotracheal tubes, anesthetic kits, oxygen face masks, heat and moisture exchanging filters, anesthesia masks, laryngoscope blades, suction sets, and nasal oxygen cannulas; other medical devices, such as KN95 masks and filtering half mask; and visualized prostatic dilatation catheters. It also exports its products to approximately 30 countries in Asia, Africa, Europe, North America, South America, and Oceania. WORK Medical Technology Group LTD was founded in 2002 and is based in Hangzhou City, China.

How the Company Makes Money

WORK Medical Technology Group LTD generates revenue through multiple streams, primarily from the sale of its medical devices and digital health solutions. The company sells its products to hospitals, clinics, and healthcare providers, which constitutes a significant portion of its income. Additionally, WOK earns revenue through subscription services associated with its telehealth platforms, allowing healthcare providers to offer remote care solutions. Partnerships with healthcare institutions and technology companies also play a crucial role in expanding its market reach and driving sales. Furthermore, WOK may engage in research collaborations and grants that contribute to its funding and innovation efforts, enhancing its overall earnings potential.

WORK Medical Technology Group LTD Financial Statement Overview

Summary

Fundamentals are mixed: revenue has been shrinking and profitability remains negative, but the balance sheet leverage improved materially and operating/free cash flow rebounded strongly in the latest year. The key risk is still weak earnings power and an unfavorable top-line trend.

Income Statement

Profitability has deteriorated materially versus earlier years. Revenue has been shrinking for several years (2025 annual revenue down ~8% year over year and far below 2020–2021 levels), and the company is currently loss-making (2025 net margin about -11% and negative operating profit). The positive sign is a sharp improvement from 2024’s much deeper loss, with EBITDA turning slightly positive in 2025, but margins remain weak and the top-line trajectory is still a clear headwind.

Balance Sheet

Leverage looks more manageable in the latest year, with debt-to-equity improving to ~0.35 in 2025 (down from ~1.02 in 2024), suggesting reduced balance-sheet risk versus the prior year. Equity remains meaningful relative to assets, but returns are currently negative due to net losses (2025 return on equity around -6%), indicating the balance sheet is stable yet not being translated into attractive shareholder returns.

Cash Flow

Cash generation improved significantly in 2025, with strong positive operating cash flow (~$6.2M) and positive free cash flow (~$4.9M) after a very weak 2024. However, cash-flow consistency is a concern: operating and free cash flow have been volatile across the period (several negative years), and 2025 free-cash-flow growth is sharply negative versus the prior year’s reported base, highlighting uneven conversion and higher uncertainty around sustainability.

Breakdown	Sep 2025	Sep 2024	Sep 2023	Sep 2022	Sep 2021
Income Statement
Total Revenue	9.85M	11.51M	13.57M	19.71M	45.86M
Gross Profit	2.34M	2.87M	4.14M	4.42M	8.64M
EBITDA	339.37K	-1.71M	2.08M	4.72M	11.87M
Net Income	-1.07M	-3.49M	112.03K	865.21K	5.96M
Balance Sheet
Total Assets	33.16M	36.25M	29.96M	25.54M	30.66M
Cash, Cash Equivalents and Short-Term Investments	4.09M	6.56M	1.60M	731.18K	508.71K
Total Debt	6.45M	13.47M	9.10M	6.30M	6.60M
Total Liabilities	11.99M	20.18M	18.97M	14.35M	19.26M
Stockholders Equity	18.35M	13.19M	9.88M	10.00M	10.04M
Cash Flow
Free Cash Flow	4.91M	-11.49M	1.63M	-4.27M	-7.24M
Operating Cash Flow	6.24M	-2.23M	2.21M	-2.26M	-7.18M
Investing Cash Flow	-7.61M	-9.06M	-583.30K	-1.35M	-60.00K
Financing Cash Flow	-898.21K	15.66M	-728.72K	3.57M	7.99M

WORK Medical Technology Group LTD Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For WOK, the sentiment is Negative. The current price of 2.1 is above the 20-day moving average (MA) of 1.44, below the 50-day MA of 2.32, and below the 200-day MA of 3691.26, indicating a bearish trend. The MACD of -9.72 indicates Negative momentum. The RSI at 28.38 is Positive, neither overbought nor oversold. The STOCH value of 34.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for WOK.

WORK Medical Technology Group LTD Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EKSO	54 Neutral	$36.13M	-2.00	-85.01%	―	-16.59%	43.20%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
WOK	47 Neutral	$1.63M	-0.01	―	―	―	―
LUCY	43 Neutral	$5.99M	-0.43	-74.10%	―	53.22%	72.69%
GCTK	42 Neutral	$1.57M	>-0.01	―	―	―	60.83%

WORK Medical Technology Group LTD Corporate Events

WORK Medical Technology Group Plans Major Capital Restructuring Ahead of February 25 AGM

WORK Medical Technology Group LTD has called its annual general meeting of shareholders for February 25, 2026, in Hangzhou with virtual participation available, targeting both Class A and Class B shareholders. The meeting will consider a sweeping overhaul of the company’s capital structure, including a massive increase in authorized share capital followed by a deep par-value reduction to US$0.00001 and a reorganization that reshapes its capital base.

Shareholders will be asked to approve a share consolidation at a ratio of up to 4,000 existing shares into one, with no fractional shares issued and rounding up to whole shares, giving the board broad discretion on the final ratio over the next two years. The agenda also includes re-election of five directors, confirmation of HTL International, LLC as auditor for the fiscal year ending September 30, 2026, and authority to adjourn the meeting, steps that collectively aim to streamline governance and provide flexibility for future financing or corporate actions.

The most recent analyst rating on (WOK) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on WORK Medical Technology Group LTD stock, see the WOK Stock Forecast page.

WORK Medical Technology Group Sells New Class B Shares to COO’s Entity, Consolidating Voting Control

On December 30, 2025, WORK Medical Technology Group LTD entered into a securities purchase agreement with LWY GROUP LTD, an existing shareholder wholly owned by the company’s chief operating officer, Baiming Yu, for the issuance and sale of 100,000 Class B ordinary shares at an aggregate purchase price of $500,000 under Regulation S of the U.S. Securities Act of 1933. The transaction, which was approved by the company’s audit committee and full board and is expected to close on or about January 13, 2026, will increase Yu’s beneficial holdings to 100,625 Class B shares, representing approximately 54.96% of the company’s total voting power, thereby consolidating insider control and potentially shaping future corporate governance and strategic direction for shareholders.

The most recent analyst rating on (WOK) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on WORK Medical Technology Group LTD stock, see the WOK Stock Forecast page.

WORK Medical Technology Group Executes 100-for-1 Share Consolidation to Maintain Nasdaq Listing

On October 21, 2025, WORK Medical Technology Group LTD shareholders approved resolutions authorizing one or more consolidations of the company’s authorized, issued and outstanding ordinary shares within a range of 2:1 to 250:1, along with adopting an amended and restated memorandum of association to reflect any such changes. Following this approval, the board resolved on November 29, 2025 to implement a 100:1 share consolidation, which took effect on December 29, 2025, reducing the company’s outstanding ordinary shares from about 122.0 million to approximately 1.22 million and similarly consolidating its authorized share capital, with fractional shares rounded up and electronic holdings adjusted automatically, in order to raise the per-share price and allow the company to more quickly regain compliance with Nasdaq’s minimum bid price requirement and reduce the risk of delisting; the Class A ordinary shares continue to trade on Nasdaq under the symbol “WOK” with a new CUSIP.

The most recent analyst rating on (WOK) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on WORK Medical Technology Group LTD stock, see the WOK Stock Forecast page.

WORK Medical Technology Group Enters Sales Agreement to Raise $200 Million

On November 20, 2025, WORK Medical Technology Group LTD announced a new sales agreement with AC Sunshine Securities, LLC, allowing the company to offer and sell Class A ordinary shares through the sales agent. The agreement enables the company to raise up to $200 million, with shares sold at the company’s discretion, reflecting a strategic move to enhance market liquidity and financial flexibility. This development could potentially impact the company’s market position and provide stakeholders with opportunities for investment.

The most recent analyst rating on (WOK) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on WORK Medical Technology Group LTD stock, see the WOK Stock Forecast page.